Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Owonikoko, T. K.Kim, H. R.Govindan, R.Ready, N.Reck, M.Peters, S.Dakhil, S. R.Navarro, A.Rodriguez-Cid, J.Schenker, M.Lee, J. S.Gutierrez, V.Percent, I.Morgensztern, D.Fairchild, J.Baudelet, C.Park, K.2025-01-072025-01-072019-04-010923-7534https://hdl.handle.net/10668/24385enNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 studyconference outputopen access10.1093/annonc/mdz0941569-8041http://www.annalsofoncology.org/article/S0923753419302595/pdf478089000208